4D Molecular Therapeutics (FDMT) EBITDA Margin (QoQ) (2020 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) EBITDA Margin (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37,899.00 |
| Mar 31, 2026 | -243,344.00 |
| Dec 31, 2025 | 6.80 Mn |
| Sep 30, 2025 | 32.84 Mn |
| Jun 30, 2025 | -1.34 Mn |
| Mar 31, 2025 | 522.87 Mn |
| Dec 31, 2024 | -390.73 Mn |
| Sep 30, 2024 | -85.53 Mn |
| Jun 30, 2024 | -71.29 Mn |
| Mar 31, 2024 | -32.91 Mn |
| Dec 31, 2023 | 19.30 Mn |
| Sep 30, 2023 | 1.34 Mn |
| Jun 30, 2023 | -334,334.00 |
| Mar 31, 2023 | -779,956.00 |
| Dec 31, 2022 | 299,587.00 |
| Sep 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | -1.54 Mn |
| Mar 31, 2022 | 2.48 Mn |
| Dec 31, 2021 | -2.53 Mn |
| Sep 30, 2021 | -160,683.00 |